EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|October 1, 2004
Tissue adhesive alternative to sutures, staples
National report - Many dermatologists, especially pediatric dermatologists, have embraced 2-octyl cyanoacrylate tissue adhesive (Dermabond, Ethicon) as an alternative to using standard sutures and staples in selected patients. Dermabond has evolved, as a result of early complaints about dripping and smearing, to offer a new, higher-viscosity formulation. But it's unclear how effective the tissue adhesive is when skin tension exists.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
4
Repigmentation With Upadacitinib Continues Through Week 76 in Non-Segmental Vitiligo
5